Global Crizotinib API Market Growth 2024-2030

Publication ID:

LPI11241819

Publication Date:

November 18, 2024

Pages:

142

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Crizotinib is an active pharmaceutical ingredient (API) used as a targeted therapy for cancers with ALK gene alterations,primarily non-small cell lung cancer (NSCLC).It works by inhibiting the ALK protein, which is involved in tumor growth.
The global Crizotinib API market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淐rizotinib API Industry Forecast鈥� looks at past sales and reviews total world Crizotinib API sales in 2023, providing a comprehensive analysis by region and market sector of projected Crizotinib API sales for 2024 through 2030. With Crizotinib API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Crizotinib API industry.
This Insight Report provides a comprehensive analysis of the global Crizotinib API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Crizotinib API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Crizotinib API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Crizotinib API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Crizotinib API.
United States market for Crizotinib API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Crizotinib API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Crizotinib API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Crizotinib API players cover MSN Laboratories, Greencross, Hetero Labs, Vama Lifecare, Croissance Biomed, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Crizotinib API market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
笔耻谤颈迟测鈮�99%
Purity<99%
Segmentation by Application:
Online Sales
Offline Sales
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
MSN Laboratories
Greencross
Hetero Labs
Vama Lifecare
Croissance Biomed
Medicine House
Apothecon Pharmaceuticals
Tocris Bioscience
Selleck Chemicals
Cayman Chemical
Anant Pharmaceuticals
Adooq Bioscience
Focus Biomolecules
LC Laboratories
Hefei Home Sunshine Pharmaceutical Technology
Chongqing Huapont Shengchem Pharm
Xuzhou Wanbang Jinqiao Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Crizotinib API market?
What factors are driving Crizotinib API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Crizotinib API market opportunities vary by end market size?
How does Crizotinib API break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Crizotinib API Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Crizotinib API by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Crizotinib API by Country/Region, 2019, 2023 & 2030
2.2 Crizotinib API Segment by Type
2.2.1 笔耻谤颈迟测鈮�99%
2.2.2 Purity<99%
2.3 Crizotinib API Sales by Type
2.3.1 Global Crizotinib API Sales Market Share by Type (2019-2024)
2.3.2 Global Crizotinib API Revenue and Market Share by Type (2019-2024)
2.3.3 Global Crizotinib API Sale Price by Type (2019-2024)
2.4 Crizotinib API Segment by Application
2.4.1 Online Sales
2.4.2 Offline Sales
2.5 Crizotinib API Sales by Application
2.5.1 Global Crizotinib API Sale Market Share by Application (2019-2024)
2.5.2 Global Crizotinib API Revenue and Market Share by Application (2019-2024)
2.5.3 Global Crizotinib API Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Crizotinib API Breakdown Data by Company
3.1.1 Global Crizotinib API Annual Sales by Company (2019-2024)
3.1.2 Global Crizotinib API Sales Market Share by Company (2019-2024)
3.2 Global Crizotinib API Annual Revenue by Company (2019-2024)
3.2.1 Global Crizotinib API Revenue by Company (2019-2024)
3.2.2 Global Crizotinib API Revenue Market Share by Company (2019-2024)
3.3 Global Crizotinib API Sale Price by Company
3.4 Key Manufacturers Crizotinib API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Crizotinib API Product Location Distribution
3.4.2 Players Crizotinib API Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Crizotinib API by Geographic Region
4.1 World Historic Crizotinib API Market Size by Geographic Region (2019-2024)
4.1.1 Global Crizotinib API Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Crizotinib API Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Crizotinib API Market Size by Country/Region (2019-2024)
4.2.1 Global Crizotinib API Annual Sales by Country/Region (2019-2024)
4.2.2 Global Crizotinib API Annual Revenue by Country/Region (2019-2024)
4.3 Americas Crizotinib API Sales Growth
4.4 APAC Crizotinib API Sales Growth
4.5 Europe Crizotinib API Sales Growth
4.6 Middle East & Africa Crizotinib API Sales Growth
5 Americas
5.1 Americas Crizotinib API Sales by Country
5.1.1 Americas Crizotinib API Sales by Country (2019-2024)
5.1.2 Americas Crizotinib API Revenue by Country (2019-2024)
5.2 Americas Crizotinib API Sales by Type (2019-2024)
5.3 Americas Crizotinib API Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Crizotinib API Sales by Region
6.1.1 APAC Crizotinib API Sales by Region (2019-2024)
6.1.2 APAC Crizotinib API Revenue by Region (2019-2024)
6.2 APAC Crizotinib API Sales by Type (2019-2024)
6.3 APAC Crizotinib API Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Crizotinib API by Country
7.1.1 Europe Crizotinib API Sales by Country (2019-2024)
7.1.2 Europe Crizotinib API Revenue by Country (2019-2024)
7.2 Europe Crizotinib API Sales by Type (2019-2024)
7.3 Europe Crizotinib API Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Crizotinib API by Country
8.1.1 Middle East & Africa Crizotinib API Sales by Country (2019-2024)
8.1.2 Middle East & Africa Crizotinib API Revenue by Country (2019-2024)
8.2 Middle East & Africa Crizotinib API Sales by Type (2019-2024)
8.3 Middle East & Africa Crizotinib API Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Crizotinib API
10.3 Manufacturing Process Analysis of Crizotinib API
10.4 Industry Chain Structure of Crizotinib API
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Crizotinib API Distributors
11.3 Crizotinib API Customer
12 World Forecast Review for Crizotinib API by Geographic Region
12.1 Global Crizotinib API Market Size Forecast by Region
12.1.1 Global Crizotinib API Forecast by Region (2025-2030)
12.1.2 Global Crizotinib API Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Crizotinib API Forecast by Type (2025-2030)
12.7 Global Crizotinib API Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 MSN Laboratories
13.1.1 MSN Laboratories Company Information
13.1.2 MSN Laboratories Crizotinib API Product Portfolios and Specifications
13.1.3 MSN Laboratories Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 MSN Laboratories Main Business Overview
13.1.5 MSN Laboratories Latest Developments
13.2 Greencross
13.2.1 Greencross Company Information
13.2.2 Greencross Crizotinib API Product Portfolios and Specifications
13.2.3 Greencross Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Greencross Main Business Overview
13.2.5 Greencross Latest Developments
13.3 Hetero Labs
13.3.1 Hetero Labs Company Information
13.3.2 Hetero Labs Crizotinib API Product Portfolios and Specifications
13.3.3 Hetero Labs Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Hetero Labs Main Business Overview
13.3.5 Hetero Labs Latest Developments
13.4 Vama Lifecare
13.4.1 Vama Lifecare Company Information
13.4.2 Vama Lifecare Crizotinib API Product Portfolios and Specifications
13.4.3 Vama Lifecare Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Vama Lifecare Main Business Overview
13.4.5 Vama Lifecare Latest Developments
13.5 Croissance Biomed
13.5.1 Croissance Biomed Company Information
13.5.2 Croissance Biomed Crizotinib API Product Portfolios and Specifications
13.5.3 Croissance Biomed Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Croissance Biomed Main Business Overview
13.5.5 Croissance Biomed Latest Developments
13.6 Medicine House
13.6.1 Medicine House Company Information
13.6.2 Medicine House Crizotinib API Product Portfolios and Specifications
13.6.3 Medicine House Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Medicine House Main Business Overview
13.6.5 Medicine House Latest Developments
13.7 Apothecon Pharmaceuticals
13.7.1 Apothecon Pharmaceuticals Company Information
13.7.2 Apothecon Pharmaceuticals Crizotinib API Product Portfolios and Specifications
13.7.3 Apothecon Pharmaceuticals Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Apothecon Pharmaceuticals Main Business Overview
13.7.5 Apothecon Pharmaceuticals Latest Developments
13.8 Tocris Bioscience
13.8.1 Tocris Bioscience Company Information
13.8.2 Tocris Bioscience Crizotinib API Product Portfolios and Specifications
13.8.3 Tocris Bioscience Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Tocris Bioscience Main Business Overview
13.8.5 Tocris Bioscience Latest Developments
13.9 Selleck Chemicals
13.9.1 Selleck Chemicals Company Information
13.9.2 Selleck Chemicals Crizotinib API Product Portfolios and Specifications
13.9.3 Selleck Chemicals Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Selleck Chemicals Main Business Overview
13.9.5 Selleck Chemicals Latest Developments
13.10 Cayman Chemical
13.10.1 Cayman Chemical Company Information
13.10.2 Cayman Chemical Crizotinib API Product Portfolios and Specifications
13.10.3 Cayman Chemical Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Cayman Chemical Main Business Overview
13.10.5 Cayman Chemical Latest Developments
13.11 Anant Pharmaceuticals
13.11.1 Anant Pharmaceuticals Company Information
13.11.2 Anant Pharmaceuticals Crizotinib API Product Portfolios and Specifications
13.11.3 Anant Pharmaceuticals Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Anant Pharmaceuticals Main Business Overview
13.11.5 Anant Pharmaceuticals Latest Developments
13.12 Adooq Bioscience
13.12.1 Adooq Bioscience Company Information
13.12.2 Adooq Bioscience Crizotinib API Product Portfolios and Specifications
13.12.3 Adooq Bioscience Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Adooq Bioscience Main Business Overview
13.12.5 Adooq Bioscience Latest Developments
13.13 Focus Biomolecules
13.13.1 Focus Biomolecules Company Information
13.13.2 Focus Biomolecules Crizotinib API Product Portfolios and Specifications
13.13.3 Focus Biomolecules Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Focus Biomolecules Main Business Overview
13.13.5 Focus Biomolecules Latest Developments
13.14 LC Laboratories
13.14.1 LC Laboratories Company Information
13.14.2 LC Laboratories Crizotinib API Product Portfolios and Specifications
13.14.3 LC Laboratories Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 LC Laboratories Main Business Overview
13.14.5 LC Laboratories Latest Developments
13.15 Hefei Home Sunshine Pharmaceutical Technology
13.15.1 Hefei Home Sunshine Pharmaceutical Technology Company Information
13.15.2 Hefei Home Sunshine Pharmaceutical Technology Crizotinib API Product Portfolios and Specifications
13.15.3 Hefei Home Sunshine Pharmaceutical Technology Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Hefei Home Sunshine Pharmaceutical Technology Main Business Overview
13.15.5 Hefei Home Sunshine Pharmaceutical Technology Latest Developments
13.16 Chongqing Huapont Shengchem Pharm
13.16.1 Chongqing Huapont Shengchem Pharm Company Information
13.16.2 Chongqing Huapont Shengchem Pharm Crizotinib API Product Portfolios and Specifications
13.16.3 Chongqing Huapont Shengchem Pharm Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Chongqing Huapont Shengchem Pharm Main Business Overview
13.16.5 Chongqing Huapont Shengchem Pharm Latest Developments
13.17 Xuzhou Wanbang Jinqiao Pharmaceutical
13.17.1 Xuzhou Wanbang Jinqiao Pharmaceutical Company Information
13.17.2 Xuzhou Wanbang Jinqiao Pharmaceutical Crizotinib API Product Portfolios and Specifications
13.17.3 Xuzhou Wanbang Jinqiao Pharmaceutical Crizotinib API Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Xuzhou Wanbang Jinqiao Pharmaceutical Main Business Overview
13.17.5 Xuzhou Wanbang Jinqiao Pharmaceutical Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂